TCA Cycle and Mitochondrial Respiration Readouts
Four Measurements That Are Not Interchangeable
| Measurement | What it reports | Representative method |
|---|---|---|
| TCA turnover | Carbon flux through the cycle | ¹³C substrate tracing with isotopologue analysis |
| Electron transport rate | Oxygen consumption by the chain | OCR, in intact or permeabilised cells |
| Proton gradient | Membrane potential or ΔpH | Fluorescent dyes or electrode-based estimates |
| ATP synthesis | Mitochondrial ATP production | ATP-linked respiration, or ATP measurement with inhibitors |
A cell can increase TCA turnover without increasing electron transport (if more carbon exits as citrate), or increase electron transport without increasing ATP synthesis (if the chain is uncoupled by proton leak). Reporting "mitochondrial function increased" from any single row is the most common overreach in this area.
Readout note. OCR is the rate of oxygen consumption under the assay's conditions. It depends on the substrate supplied, the cell density, the buffer and the temperature. It is not ATP production, and it is not a measure of mitochondrial mass — a point that matters because mitochondrial content changes with treatment, and OCR normalised to cell number will then track content as much as function.
Part 1 — Readouts by Question
| Question | Best available approach | Caveat |
|---|---|---|
| Is the cycle turning over? | ¹³C-glucose or ¹³C-glutamine, citrate/α-ketoglutarate/malate isotopologues | Turnover and pool size both affect labelling; needs modelling for rates |
| Is the chain active? | Basal OCR in defined substrate conditions | Substrate mix, not the chain, is often limiting |
| How much capacity is there? | Maximal OCR after titrated uncoupler | Over-titration damages membranes; single-concentration conventions are unreliable |
| How much is used for ATP? | Oligomycin-sensitive OCR, with a stated calculation | Assumes complete ATP synthase inhibition |
| Is the chain intact? | Substrate-specific respiration in permeabilised cells | Requires digitonin titration; over-permeabilisation loses cytochrome c |
| Is the gradient maintained? | Dye-based potential measurement | Dye distribution depends on potential itself; quantitation is difficult |
The fourth row deserves emphasis. "ATP-linked respiration" is a derived quantity: it is the difference between a basal rate and a post-oligomycin rate, and it inherits the assumptions of both. Reporting the derived value without the raw rates makes the calculation unauditable.
Part 2 — Substrate-Specific Respiration
The most informative mitochondrial assay in current use is substrate-specific respiration in permeabilised cells, because it controls the substrate rather than the cell.
| Substrate combination | Route tested | Common purpose |
|---|---|---|
| Pyruvate + malate | Complex I via PDH | PDH-axis and complex I capacity |
| Glutamate + malate | Complex I, bypassing PDH | Complex I independent of pyruvate entry |
| Succinate + rotenone | Complex II | Distinguishes complex II from complex I |
| Palmitoyl-carnitine + malate | Fatty acid oxidation | FAO capacity and CPT1 dependence |
| TMPD + ascorbate | Complex IV | Terminal capacity |
Two technical requirements determine whether the data mean anything. Digitonin must be titrated for each cell type: too little leaves membranes intact and the substrates do not reach the matrix; too much permeabilises the outer membrane and cytochrome c leaks out, collapsing complex IV capacity. The assay medium must be defined, because the same cells give different maximal rates in different buffer compositions.
Part 3 — Isotope Tracing for the Cycle
| Observation | Common interpretation | Alternative to exclude |
|---|---|---|
| Citrate m+2 from [U-¹³C]glucose | One PDH turn plus one cycle turn | Pyruvate cycling dilutes label |
| Citrate m+3, m+4 | Pyruvate carboxylation or multiple turns | Pool heterogeneity; needs modelling |
| Succinate and fumarate labelling asymmetry | Cycle turnover and exchange with the pool | Reversal of succinate dehydrogenase under some conditions |
| Glutamine-derived malate and citrate | Anaplerosis and reductive carboxylation | Compartment mixing in bulk extracts |
Important distinction. Isotopologue patterns report the routes by which carbon arrived; they do not report the rate. Converting labelling into flux requires extracellular rates for the substrates, a network model and a fit assessment — the standard ¹³C-metabolic flux analysis workflow. Without those, the output is a routing statement.
A second distinction matters for the cycle specifically: anaplerosis and cataplerosis are not visible in pool sizes. Glutamine can be feeding the cycle steadily while total citrate is unchanged, because efflux to lipid synthesis balances influx. Only tracing (or a mass-balance design) reveals the traffic.
Part 4 — The Inhibitor Panel and Its Assumptions
| Agent | Target | Assumption it relies on |
|---|---|---|
| Oligomycin | ATP synthase | Complete inhibition at the concentration used |
| FCCP or BAM15 | Uncoupler | Titrated to maximal respiration without damage; not assumed |
| Rotenone | Complex I | Complete block; effective in the cell type used |
| Antimycin A | Complex III | Complete block |
| TTFA | Complex II | Specificity at the concentration used |
| 3-nitropropionate | Succinate dehydrogenase | Irreversible; recovery requires new enzyme |
Caveat on single-concentration conventions. The widely used sequence (oligomycin, then uncoupler, then rotenone plus antimycin A) yields interpretable parameters only if each agent is at an effective and non-toxic concentration. A titration of the uncoupler in the same plate is worth the wells: it converts "maximal respiration" from a convention into a measurement, and it reveals toxicity that a fixed dose conceals.
A second caveat: several of these agents are dissolved in ethanol or DMSO, and the vehicle effects on respiration are not negligible at the volumes used in small wells. Vehicle controls belong in the plate, not in the methods section.
Part 5 — Three Levels of Evidence
| Level | Claim | Minimum evidence | What does not count |
|---|---|---|---|
| 1. Activity | Oxygen consumption changed | Normalised OCR in defined substrate conditions, with raw rates | Raw plate values; a single well |
| 2. Capacity or route | A specific complex or substrate route changed | Substrate-specific respiration in permeabilised cells, or a titration | Basal OCR alone |
| 3. Dependence | The change is required for a phenotype | Perturbation of the relevant complex or transporter, with rescue, under a constraint | Correlation between OCR and growth |
Part 6 — Model and Assay Requirements
| Requirement | Why |
|---|---|
| Defined assay medium | Substrate composition sets basal rate |
| Digitonin titration, if permeabilised | Otherwise substrates do not reach the matrix, or cytochrome c is lost |
| Uncoupler titration | Converts maximal respiration into a measurement |
| Plate layout without edge effects | Evaporation changes rates in perimeter wells |
| Normalisation basis stated | Viable count, DNA or protein; each has limitations |
| Mitochondrial content measured | Separates content from function |
| Temperature and mixing controlled | Both affect oxygen diffusion and consumption |
Part 7 — Failures That Recur
- • Basal OCR reported as mitochondrial function, without substrate or normalisation context.
- • Maximal respiration from a single uncoupler concentration.
- • Permeabilised-cell data without a digitonin titration, or without a cytochrome c check.
- • "ATP-linked respiration" reported without the raw rates used to derive it.
- • Mitochondrial mass and mitochondrial function conflated. Content should be measured (mtDNA, a complex subunit, or fluorescence) alongside the rate.
- • Isotopologue patterns reported as fluxes.
- • Vehicle effects omitted for ethanol- or DMSO-dissolved inhibitors.
- • Edge wells included in a plate-based assay without a layout control.
Part 8 — Where This Article Connects
This article supplies the mitochondrial half of the pillar's flux question. The glycolysis–OXPHOS switch article defines partition; this one defines what the oxidative side can and cannot measure. The Seahorse protocol articles that follow in this cluster handle instrument parameters and baseline troubleshooting, which are assay-execution problems rather than interpretation problems.
If you need substrate-specific respirometry with digitonin and uncoupler titration built in, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Respiratory capacity, substrate preference and coupling efficiency vary with cell type, medium, passage and assay conditions; the values implied by these methods are assay-dependent, not absolute properties of the cell.
A change in oxygen consumption does not establish a change in ATP synthesis, and a change in ATP synthesis does not establish a change in TCA turnover.
Scientific interpretation and experimental design
- • Four measurements, four questions. Turnover, transport, gradient, synthesis.
- • OCR is not mass. Measure content when the treatment could change it.
- • Titrate the uncoupler. A fixed dose is a convention, not a measurement.
- • Titrate digitonin. Both under- and over-permeabilisation produce plausible wrong answers.
- • Derived values need raw rates. Otherwise the calculation cannot be checked.
- • Labelling is routing. Flux requires extracellular rates and a model.
Selected references for further reading
- • Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochemical Journal. 2011;435:297–312.
- • Divakaruni AS, Jastroch M. A practical guide for the analysis, standardization, and interpretation of oxygen consumption measurements. Nature Metabolism. 2022;4:978–994.
- • Buescher JM, et al. A roadmap for interpreting ¹³C metabolite labeling patterns from cells. Current Opinion in Biotechnology. 2015;34:189–201.
- • Antoniewicz MR. A guide to ¹³C metabolic flux analysis for the cancer biologist. Experimental & Molecular Medicine. 2018;50:1–13.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »